Skip to main content

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Written by Customer Service on . Posted in Public Companies.

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024.

Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company’s first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder caused by single nucleotide variants (SNVs) in the SERPINA1 gene.

Oral Presentation Information:
Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
Speaker: Venkat Krishnamurthy
Date: Monday, October 7
Time: 3:20 p.m. ET

Poster Presentation Information:
Title: Purification of Human ADAR Enables Evaluation of Oligo-Directed RNA Editing in a Cell-Free Environment that Predicts In Vivo Activity
Name: Agya Karki, Ph.D., Senior Scientist
Poster Number: P133

Title: Using ADAR1 chimeric eCLIP to understand the on-target and off-target behaviors of RNA editing oligonucleotides
Name: Zhiji Ren, Ph.D., Principal Scientist
Poster Number: P228

About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Contact Information
Investors
IR@korrobio.com 

Media
Glenn Silver 
FINN Partners 
Glenn.silver@finnpartners.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.